Home › Funds › MFS Investment Management › GILD
MFS Investment Management position in GILD
GILEAD SCIENCES INC · Health Care
MFS Investment Management reported holding 11,461,347 shares of GILD (GILEAD SCIENCES INC) in its Q3 2026 13F filing — a position valued at US$1.77B, representing 0.60% of its reported portfolio and ranking #33 among its reported holdings. MFS Investment Management has disclosed GILD holdings in 53 of the last 55 reported quarters, going back to Q1 2013.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How MFS Investment Management's GILD position evolved
MFS Investment Management first disclosed a stake in GILD in Q1 2013 at 6,780,185 shares (US$331.82B). The position peaked in Q4 2013 at 7,230,601 shares, worth US$543.02B. Across 53 filings, MFS Investment Management increased the stake 23 time(s), trimmed it 27 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 11,461,347 shares valued at US$1.77B — an increase of 4,809,514 shares quarter over quarter.. Notable position changes include a 100% trim in Q3 2017, a 116% increase in Q1 2022 (shares rose 3% over the following quarter), a 3764% increase in Q4 2025 (shares rose 14% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2013 | 6.78M | $331.82B | New |
| Q2 2013 | 6.26M | $321.16B | Reduce |
| Q3 2013 | 7.79M | $489.57B | Add |
| Q4 2013 | 7.23M | $543.02B | Reduce |
| Q1 2014 | 5.42M | $383.94B | Reduce |
| Q2 2014 | 2.94M | $244.17M | Reduce |
| Q3 2014 | 2.79M | $297.11M | Reduce |
| Q4 2014 | 2.00M | $188.99B | Reduce |
| Q1 2015 | 1.59M | $156.34B | Reduce |
| Q2 2015 | 1.76M | $205.85B | Add |
| Q3 2015 | 2.41M | $236.76M | Add |
| Q4 2015 | 2.52M | $254.70M | Add |
| Q1 2016 | 2.87M | $263.24M | Add |
| Q2 2016 | 2.70M | $224.95M | Reduce |
| Q3 2016 | 2.51M | $198.45M | Reduce |
| Q4 2016 | 2.45M | $175.26M | Reduce |
| Q1 2017 | 1.73M | $117.33M | Reduce |
| Q2 2017 | 1.37M | $96.62M | Reduce |
| Q3 2017 | 6.07K | $492.00K | Reduce |
| Q4 2017 | 7.50K | $537.00K | Add |
| Q1 2018 | 5.78K | $436.00K | Reduce |
| Q2 2018 | 5.00K | $354.00K | Reduce |
| Q3 2018 | 7.73K | $597.00K | Add |
| Q4 2018 | 6.48K | $405.00K | Reduce |
| Q1 2019 | 5.64K | $367.00K | Reduce |
| Q2 2019 | 5.85K | $395.00K | Add |
| Q3 2019 | 6.41K | $406.00K | Add |
| Q4 2019 | 5.74K | $373.00K | Reduce |
| Q3 2020 | 356.39K | $22.52M | New |
| Q4 2020 | 429.31K | $25.01M | Add |
| Q1 2021 | 416.28K | $26.90M | Reduce |
| Q2 2021 | 461.97K | $31.81M | Add |
| Q3 2021 | 178.41K | $12.46M | Reduce |
| Q4 2021 | 260.65K | $18.93M | Add |
| Q1 2022 | 564.18K | $33.54M | Add |
| Q2 2022 | 576.03K | $35.60M | Add |
| Q3 2022 | 564.56K | $34.83M | Reduce |
| Q4 2022 | 534.56K | $45.89M | Reduce |
| Q1 2023 | 383.80K | $31.84M | Reduce |
| Q2 2023 | 275.33K | $21.22M | Reduce |
| Q3 2023 | 278.56K | $20.88M | Add |
| Q4 2023 | 84.99K | $6.88M | Reduce |
| Q1 2024 | 85.28K | $6.25M | Hold |
| Q2 2024 | 85.80K | $5.89M | Add |
| Q3 2024 | 75.41K | $6.32M | Reduce |
| Q4 2024 | 75.92K | $7.01M | Add |
| Q1 2025 | 94.29K | $10.56M | Add |
| Q2 2025 | 114.29K | $12.67M | Add |
| Q3 2025 | 109.31K | $12.13M | Reduce |
| Q4 2025 | 4.22M | $518.37M | Add |
| Q1 2026 | 6.28M | $909.69M | Add |
| Q2 2026 | 6.65M | $876.75M | Add |
| Q3 2026 | 11.46M | $1.77B | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GILD and 13F data
GILD (GILEAD SCIENCES INC) is a Health Care company. 33 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.68B), Invesco Ltd (US$5.76B), Capital World Investors (US$5.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GILD
- Fidelity Management & Research (FMR) 58.27M sh · $8.68B · Q3 2026
- Invesco Ltd 38.66M sh · $5.76B · Q3 2026
- Capital World Investors 35.93M sh · $5.36B · Q3 2026
- Capital World Investors 40.99M sh · $5.18B · Q2 2026
- PRICE T ROWE ASSOCIATES INC /MD/ 30.00M sh · $3.79B · Q2 2026
- Capital Research Global Investors 23.98M sh · $3.57B · Q3 2026
- Dodge & Cox 23.68M sh · $2.99B · Q2 2026
- DODGE & COX 23.68M sh · $2.99B · Q2 2026
- Amundi US 11.26M sh · $1.68B · Q3 2026
- Deutsche Bank AG 9.61M sh · $1.43B · Q3 2026
- Boston Partners 6.52M sh · $970.37M · Q3 2026
More on MFS Investment Management
FAQ
How long has MFS Investment Management held GILD?
MFS Investment Management has disclosed GILD holdings in 53 of the last 55 reported quarters, going back to Q1 2013.
What is MFS Investment Management's current position in GILD?
As of Q3 2026, MFS Investment Management holds 11.46M shares of GILD (GILEAD SCIENCES INC), valued at $1.77B, representing 0.60% of its reported portfolio and ranking #33.
Has MFS Investment Management been buying or selling GILD?
In the latest 13F filing (Q3 2026), MFS Investment Management increased its position in GILD. The position peaked in Q4 2013 at 7.23M shares.
Which other funds hold GILD?
Other major institutional holders of GILD include Fidelity Management & Research (FMR), Invesco Ltd, Capital World Investors, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.